Antipsychotic augmentation vs. monotherapy in schizophrenia: systematic review, meta-analysis and meta-regression analysis
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Antipsychotic augmentation vs. monotherapy in schizophrenia: systematic review, meta-analysis and meta-regression analysis
Authors
Keywords
-
Journal
World Psychiatry
Volume 16, Issue 1, Pages 77-89
Publisher
Wiley
Online
2017-01-27
DOI
10.1002/wps.20387
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Efficacy and Safety of Brexpiprazole for the Treatment of Acute Schizophrenia: A 6-Week Randomized, Double-Blind, Placebo-Controlled Trial
- (2015) Christoph U. Correll et al. AMERICAN JOURNAL OF PSYCHIATRY
- Adjunctive aripiprazole in the treatment of risperidone-induced hyperprolactinemia: A randomized, double-blind, placebo-controlled, dose–response study
- (2015) Jing-Xu Chen et al. PSYCHONEUROENDOCRINOLOGY
- Initial Severity of Schizophrenia and Efficacy of Antipsychotics
- (2015) Toshi A. Furukawa et al. JAMA Psychiatry
- Negative symptoms of schizophrenia: Clinical characteristics, pathophysiological substrates, experimental models and prospects for improved treatment
- (2014) Mark J. Millan et al. EUROPEAN NEUROPSYCHOPHARMACOLOGY
- Equipercentile linking of the BPRS and the PANSS
- (2013) S. Leucht et al. EUROPEAN NEUROPSYCHOPHARMACOLOGY
- Augmentation of Clozapine With Ziprasidone in Refractory Schizophrenia
- (2013) Maria Rosaria A. Muscatello et al. JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
- Association of prominent positive and prominent negative symptoms and functional health, well-being, healthcare-related quality of life and family burden: A CATIE analysis
- (2013) Jonathan Rabinowitz et al. SCHIZOPHRENIA RESEARCH
- Effect of Aripiprazole on Cognitive Function and Hyperprolactinemia in Patients with Schizophrenia Treated with Risperidone
- (2013) Bong Ju Lee et al. Clinical Psychopharmacology and Neuroscience
- Metabolic effects of adjunctive aripiprazole in clozapine-treated patients with schizophrenia
- (2012) X. Fan et al. ACTA PSYCHIATRICA SCANDINAVICA
- Safety and tolerability of antipsychotic polypharmacy
- (2012) Juan A Gallego et al. Expert Opinion On Drug Safety
- Augmenting Clozapine With Sertindole
- (2012) Jimmi Nielsen et al. JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
- A Systematic Review and Meta-Analysis of Recovery in Schizophrenia
- (2012) E. Jaaskelainen et al. SCHIZOPHRENIA BULLETIN
- Prevalence and correlates of antipsychotic polypharmacy: A systematic review and meta-regression of global and regional trends from the 1970s to 2009
- (2012) Juan A. Gallego et al. SCHIZOPHRENIA RESEARCH
- Efficacy of pimozide augmentation for clozapine partial responders with schizophrenia
- (2012) Handan Gunduz-Bruce et al. SCHIZOPHRENIA RESEARCH
- Augmentation of clozapine with a second antipsychotic - a meta-analysis
- (2011) D. M. Taylor et al. ACTA PSYCHIATRICA SCANDINAVICA
- Is antipsychotic polypharmacy associated with metabolic syndrome even after adjustment for lifestyle effects?: a cross-sectional study
- (2011) Fuminari Misawa et al. BMC Psychiatry
- Metabolic and endocrine adverse effects of second-generation antipsychotics in children and adolescents: A systematic review of randomized, placebo controlled trials and guidelines for clinical practice
- (2011) M. De Hert et al. EUROPEAN PSYCHIATRY
- Effect of adjunctive treatment with aripiprazole to atypical antipsychotics on cognitive function in schizophrenia patients
- (2011) Norio Yasui-Furukori et al. JOURNAL OF PSYCHOPHARMACOLOGY
- Metabolic and cardiovascular adverse effects associated with antipsychotic drugs
- (2011) Marc De Hert et al. Nature Reviews Endocrinology
- Pimozide Augmentation of Clozapine Inpatients with Schizophrenia and Schizoaffective Disorder Unresponsive to Clozapine Monotherapy
- (2011) Joseph I Friedman et al. NEUROPSYCHOPHARMACOLOGY
- Effect of aripiprazole augmentation of clozapine in schizophrenia: A double-blind, placebo-controlled study
- (2011) Maria Rosaria A. Muscatello et al. SCHIZOPHRENIA RESEARCH
- Antipsychotic polypharmacy: A survey study of prescriber attitudes, knowledge and behavior
- (2011) Christoph U. Correll et al. SCHIZOPHRENIA RESEARCH
- Effects of adjunctive treatment with aripiprazole on body weight and clinical efficacy in schizophrenia patients treated with clozapine: a randomized, double-blind, placebo-controlled trial
- (2010) W. Wolfgang Fleischhacker et al. INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY
- Adjunctive Risperidone for Partially Responsive People with Schizophrenia Treated with Clozapine
- (2010) Elaine Weiner et al. NEUROPSYCHOPHARMACOLOGY
- Advantages and disadvantages of combination treatment with antipsychotics
- (2009) Guy Goodwin et al. EUROPEAN NEUROPSYCHOPHARMACOLOGY
- Aripiprazole Augmentation in Clozapine-Treated Patients With Refractory Schizophrenia
- (2009) Jae Seung Chang et al. JOURNAL OF CLINICAL PSYCHIATRY
- A Multicenter, Randomized, Double-Blind, Placebo-Controlled, 16-Week Study of Adjunctive Aripiprazole for Schizophrenia or Schizoaffective Disorder Inadequately Treated With Quetiapine or Risperidone Monotherapy
- (2009) John M. Kane et al. JOURNAL OF CLINICAL PSYCHIATRY
- Psychiatrists’ attitude towards and knowledge of clozapine treatment
- (2009) J. Nielsen et al. JOURNAL OF PSYCHOPHARMACOLOGY
- Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
- (2009) David Moher et al. PLOS MEDICINE
- Cost of antipsychotic polypharmacy in the treatment of schizophrenia
- (2008) Baojin Zhu et al. BMC Psychiatry
- Does the Addition of a Second Antipsychotic Drug Improve Clozapine Treatment?
- (2008) C. Barbui et al. SCHIZOPHRENIA BULLETIN
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More